Literature DB >> 23134728

Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.

Chaitali Parikh1, Vasantharajan Janakiraman, Wen-I Wu, Catherine K Foo, Noelyn M Kljavin, Subhra Chaudhuri, Eric Stawiski, Brian Lee, Jie Lin, Hong Li, Maria N Lorenzo, Wenlin Yuan, Joseph Guillory, Marlena Jackson, Jesus Rondon, Yvonne Franke, Krista K Bowman, Meredith Sagolla, Jeremy Stinson, Thomas D Wu, Jiansheng Wu, David Stokoe, Howard M Stern, Barbara J Brandhuber, Kui Lin, Nicholas J Skelton, Somasekar Seshagiri.   

Abstract

The protein kinase v-akt murine thymoma viral oncogene homolog (AKT), a key regulator of cell survival and proliferation, is frequently hyperactivated in human cancers. Intramolecular pleckstrin homology (PH) domain-kinase domain (KD) interactions are important in maintaining AKT in an inactive state. AKT activation proceeds after a conformational change that dislodges the PH from the KD. To understand these autoinhibitory interactions, we generated mutations at the PH-KD interface and found that most of them lead to constitutive activation of AKT. Such mutations are likely another mechanism by which activation may occur in human cancers and other diseases. In support of this likelihood, we found somatic mutations in AKT1 at the PH-KD interface that have not been previously described in human cancers. Furthermore, we show that the AKT1 somatic mutants are constitutively active, leading to oncogenic signaling. Additionally, our studies show that the AKT1 mutants are not effectively inhibited by allosteric AKT inhibitors, consistent with the requirement for an intact PH-KD interface for allosteric inhibition. These results have important implications for therapeutic intervention in patients with AKT mutations at the PH-KD interface.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23134728      PMCID: PMC3511101          DOI: 10.1073/pnas.1204384109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

Review 1.  Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.

Authors:  Margrith E Mattmann; Sydney L Stoops; Craig W Lindsley
Journal:  Expert Opin Ther Pat       Date:  2011-06-02       Impact factor: 6.674

Review 2.  Ba/F3 cells and their use in kinase drug discovery.

Authors:  Markus Warmuth; Sungjoon Kim; Xiang-ju Gu; Gang Xia; Francisco Adrián
Journal:  Curr Opin Oncol       Date:  2007-01       Impact factor: 3.645

3.  Akt activation by growth factors is a multiple-step process: the role of the PH domain.

Authors:  A Bellacosa; T O Chan; N N Ahmed; K Datta; S Malstrom; D Stokoe; F McCormick; J Feng; P Tsichlis
Journal:  Oncogene       Date:  1998-07-23       Impact factor: 9.867

4.  Disruption of the interface between the pleckstrin homology (PH) and kinase domains of Akt protein is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2.

Authors:  Noel A Warfel; Matt Niederst; Alexandra C Newton
Journal:  J Biol Chem       Date:  2011-09-09       Impact factor: 5.157

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  Transformation of mammalian cells by constitutively active MAP kinase kinase.

Authors:  S J Mansour; W T Matten; A S Hermann; J M Candia; S Rong; K Fukasawa; G F Vande Woude; N G Ahn
Journal:  Science       Date:  1994-08-12       Impact factor: 47.728

7.  Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.

Authors:  Craig W Lindsley; Zhijian Zhao; William H Leister; Ronald G Robinson; Stanley F Barnett; Deborah Defeo-Jones; Raymond E Jones; George D Hartman; Joel R Huff; Hans E Huber; Mark E Duggan
Journal:  Bioorg Med Chem Lett       Date:  2005-02-01       Impact factor: 2.823

8.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Marco Tartaglia; Charlotte M Niemeyer; Alessandra Fragale; Xiaoling Song; Jochen Buechner; Andreas Jung; Karel Hählen; Henrik Hasle; Jonathan D Licht; Bruce D Gelb
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

Review 9.  PTEN and the PI3-kinase pathway in cancer.

Authors:  Nader Chalhoub; Suzanne J Baker
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

10.  A novel AKT3 mutation in melanoma tumours and cell lines.

Authors:  M A Davies; K Stemke-Hale; C Tellez; T L Calderone; W Deng; V G Prieto; A J F Lazar; J E Gershenwald; G B Mills
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

View more
  66 in total

1.  AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis.

Authors:  David A Kircher; Kirby A Trombetti; Mark R Silvis; Gennie L Parkman; Grant M Fischer; Stephanie N Angel; Christopher M Stehn; Sean C Strain; Allie H Grossmann; Keith L Duffy; Kenneth M Boucher; Martin McMahon; Michael A Davies; Michelle C Mendoza; Matthew W VanBrocklin; Sheri L Holmen
Journal:  Mol Cancer Res       Date:  2019-05-28       Impact factor: 5.852

2.  Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung.

Authors:  Seung-Hyun Jung; Min Sung Kim; Sung-Hak Lee; Hyun-Chun Park; Hyun Joo Choi; Leeso Maeng; Ki Ouk Min; Jeana Kim; Tae In Park; Ok Ran Shin; Tae-Jung Kim; Haidong Xu; Kyo Young Lee; Tae-Min Kim; Sang Yong Song; Charles Lee; Yeun-Jun Chung; Sug Hyung Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

3.  The Interplay between Calmodulin and Membrane Interactions with the Pleckstrin Homology Domain of Akt.

Authors:  Constance Agamasu; Ruba H Ghanam; Fei Xu; Yong Sun; Yabing Chen; Jamil S Saad
Journal:  J Biol Chem       Date:  2016-11-21       Impact factor: 5.157

4.  AKT Inhibition in Solid Tumors With AKT1 Mutations.

Authors:  David M Hyman; Lillian M Smyth; Mark T A Donoghue; Shannon N Westin; Philippe L Bedard; Emma J Dean; Hideaki Bando; Anthony B El-Khoueiry; José A Pérez-Fidalgo; Alain Mita; Jan H M Schellens; Matthew T Chang; Jonathan B Reichel; Nancy Bouvier; S Duygu Selcuklu; Tara E Soumerai; Jean Torrisi; Joseph P Erinjeri; Helen Ambrose; J Carl Barrett; Brian Dougherty; Andrew Foxley; Justin P O Lindemann; Robert McEwen; Martin Pass; Gaia Schiavon; Michael F Berger; Sarat Chandarlapaty; David B Solit; Udai Banerji; José Baselga; Barry S Taylor
Journal:  J Clin Oncol       Date:  2017-05-10       Impact factor: 44.544

5.  Genome profile in a extremely rare case of pulmonary sclerosing pneumocytoma presenting with diffusely-scattered nodules in the right lung.

Authors:  Xiangshan Fan; Ling Lin; Jianjun Wang; Yu Wang; Anning Feng; Ling Nie; Hongyan Wu; Fanqing Meng; Haodong Xu
Journal:  Cancer Biol Ther       Date:  2017-12-22       Impact factor: 4.742

Review 6.  AKT in cancer: new molecular insights and advances in drug development.

Authors:  Prabhjot S Mundi; Jasgit Sachdev; Carolyn McCourt; Kevin Kalinsky
Journal:  Br J Clin Pharmacol       Date:  2016-06-27       Impact factor: 4.335

7.  PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.

Authors:  Julia A Beaver; John P Gustin; Kyung H Yi; Anandita Rajpurohit; Matthew Thomas; Samuel F Gilbert; D Marc Rosen; Ben Ho Park; Josh Lauring
Journal:  Clin Cancer Res       Date:  2013-07-25       Impact factor: 12.531

8.  An Autoinhibitory Role for the Pleckstrin Homology Domain of Interleukin-2-Inducible Tyrosine Kinase and Its Interplay with Canonical Phospholipid Recognition.

Authors:  Sujan Devkota; Raji E Joseph; Scott E Boyken; D Bruce Fulton; Amy H Andreotti
Journal:  Biochemistry       Date:  2017-05-25       Impact factor: 3.162

Review 9.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

10.  Is There a Future for AKT Inhibitors in the Treatment of Cancer?

Authors:  Valerie M Jansen; Ingrid A Mayer; Carlos L Arteaga
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.